Home > Insider Trading > Filing (0001140361-11-031946)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184149	W Jonathan Ayers	One Idexx Drive Westbrook ME 04092	Chairman, President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-06-06	20,000	$12.60	287,540	No	4	M	Direct
Common Stock	Disposition	2011-06-06	14,918	$74.04	272,622	No	4	S	Direct
Common Stock	Disposition	2011-06-06	82	$74.63	272,540	No	4	S	Direct
Common Stock	Acquisiton	2011-06-07	20,000	$12.60	292,540	No	4	M	Direct
Common Stock	Disposition	2011-06-07	15,000	$73.46	277,540	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-06-06	20,000	$0.00	20,000	$12.60
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-06-07	20,000	$0.00	20,000	$12.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
220,320		2012-01-28	No	4	M	Direct
200,320		2012-01-28	No	4	M	Direct

Footnotes

Includes 89 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 03/31/2011.
The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $73.59 to $74.54, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $73.07 to $73.82, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant.